Ragosa Mark

CFO Mark Ragosa sells 36,722 shares at $45.92 avg, reducing stake by 75.2% to 12.1K shares at KNSA

Mark Ragosa, CFO of Kiniksa Pharmaceuticals, executed 2 separate sales on 2026-03-09 totaling 36,722 shares for $1,686,157.82, reducing his holdings from 48,808 shares to 12,086 shares—a 75.2% reduction in his stake. The sales occurred at a blended average price of $45.92, very close to the current price of $46.31 and near the 52-week high of $47.77, placing these sales in the upper range of the stock's recent trading band. Ragosa's prior trades at KNSA over the past four months show a pattern of consistent selling (5 prior sales), with positive 30-day returns averaging +4.1% across the three measurable recent transactions, and his one completed 90-day outcome (2025-12-08 sale) showing a +11.3% gain—indicating his prior KNSA sales have not preceded declines. His cross-ticker track record shows a 90d well-timed rate of 9.09% across 14 prior sells, but this provides limited predictive value for timing at this specific ticker.

CFO Mark Ragosa sold 17,845 shares of KNSA for $772,254.22 in 2 transactions on 2026-02-09, reducing holdings by 59.6%

Mark Ragosa, CFO of Kiniksa Pharmaceuticals, executed 2 separate sales totaling 17,845 shares for $772,254.22 on 2026-02-09 at prices of $42.85 and $43.72, reducing his holdings from 29,931 shares to 12,086 shares (a 59.6% reduction). The sales occurred near the current price of $44.98, which is at the 52-week high, suggesting the sales were executed at favorable valuations. At the same-ticker level, his prior 5 sales at KNSA show mixed timing outcomes (0 of 3 measurable at the 90-day mark were well-timed, with 90-day returns ranging from +1.6% to +16.3%), indicating inconsistent ability to time exits at this security. The company reported $180.9M revenue with +56.6% annual growth and is approaching profitability ($18.4M net income last quarter), though it remains unprofitable on a full-year basis, creating modest visibility into whether growth momentum will sustain. The substantial reduction in a senior executive's position warrants monitoring for context—whether this reflects portfolio rebalancing, liquidity needs, or other factors.

CFO Mark Ragosa sold 12.0K shares of KNSA at $41.89 on 2026-01-08, reducing holdings 38.6%; stock now $42.67, near 52-week high of $43.52.

Mark Ragosa, KNSA's Chief Financial Officer, sold 12,000 shares at $41.89, representing a 38.6% reduction in his shareholdings from 31.1K to 19.1K shares. The sale occurred near the stock's 52-week high of $43.52 (current price $42.67 is -2.0% below that peak). Over his same-ticker history at KNSA, Ragosa has executed 5 prior sales, with only 3 measurable 90-day outcomes showing mixed results: 0 of the 3 measured periods saw the stock decline post-sale (one showed +12.5%, another +16.3%, and a third +8.1%), indicating his prior KNSA sales were poorly timed from a downside-avoidance perspective. The company shows strong topline momentum with annual revenue growth of +56.6%, though it reported full-year net loss despite recent quarterly net income of $18.4M, creating a profile of growth combined with underlying profitability challenges.

CFO Mark Ragosa sold 42,841 shares (58.0% of holdings) at $41.49 on 2025-12-08 for $1,777,473.09; stock now $40.54.

Mark Ragosa, Chief Financial Officer, executed a substantial reduction of his KNSA position, selling 42,841 shares representing 58.0% of his pre-transaction holdings and reducing his stake from 73,927 shares to 31,086 shares. The sale occurred at $41.49, near the 52-week high of $42.71, with the stock currently trading at $40.54 (-5.1% from peak). Across his prior sales at KNSA (4 completed trades), Ragosa's timing has been poor: all 4 prior trades generated positive 90-day returns (+12.5%, +16.3%, +8.1%, +12.7%), meaning he sold before rallies and missed subsequent gains. His cross-ticker track record shows 0% well-timed sales (11.11% rate), though his 10 prior sells averaged +10.4% over 90 days, again indicating suboptimal exit timing on average. The company's fundamentals show strong quarterly revenue of $180,855,000.00 and recent profitability with net income of $18,435,000.00, alongside robust annual revenue growth of +56.6%, yet full-year results remain unprofitable, creating mixed signals about near-term sustainability.

CFO Ragosa sold 19.9K shares of KNSA at $40.94, reducing stake by 39.0% to 31.1K shares

Mark Ragosa, the CFO, executed a substantial reduction of his KNSA position, selling 19,900 shares at $40.94 for $814,706.00, which represents a 39.0% decrease from his pre-transaction holdings of 50,986 shares. This is his sixth open-market sale at KNSA in 2025, continuing a pattern of consistent share disposals; his prior five sales at this ticker show mixed near-term performance (30-day returns ranging from -3.2% to +7.9%), and none were well-timed at the 90-day horizon—the stock subsequently rose following each of those prior five sales, ranging from +5.6% to +16.3%. The stock currently trades at $40.32, just 0.7% below its 52-week high of $40.60, having gained +3.8% over 30 days and +20.8% over 90 days; KNSA's fundamentals remain mixed with strong recent revenue growth of +56.6% year-over-year but a full-year net loss on the books, tempering the near-term price strength. The consistent pattern of CFO sales at elevated valuations without evidence of well-timed exits at this ticker warrants attention to whether fundamental deterioration may be forthcoming.

CFO Mark Ragosa sold 18,889 shares of KNSA at $32.89; stock at $32.72 near 52-week high ($33.07)

Mark Ragosa, CFO of Kiniksa Pharmaceuticals, sold 18,889 shares for $621,259.21 on 2025-08-04, reducing his stake by 41.2% to 27,009 shares. The sale occurred at $32.89, just $0.35 below the 52-week high of $33.07, and the stock is currently trading at $32.72 (-1.1% from that peak). At this ticker, Ragosa's prior sales show a mixed timing pattern: 0 of 4 measurable prior sells at KNSA were well-timed at the 90-day mark (with 90d returns ranging from +5.6% to +33.8%), indicating the stock has tended to rise after his previous dispositions. The company reported strong quarterly revenue of $156,797,000.00 with +56.6% annual growth and positive net income of $17,832,000.00 in the latest quarter, though it was unprofitable on a full-year basis. The sale's timing near a 52-week high, combined with a track record of poorly-timed sells at this specific ticker, warrants close attention to whether this signals a change in his assessment of the company's prospects.

CFO Mark Ragosa sold 18.3K shares of KNSA at $28.80, reducing holdings 40.4% to 27.0K; stock rallied 37.2% in 90 days post-transaction

Mark Ragosa, Chief Financial Officer, sold 18,299 shares at $28.80 on 2025-06-03 for $527,011.20, paring his position from 45.3K to 27.0K shares (-40.4%). The sale occurred near the 52-week high of $29.52 and reflects a significant reduction in personal stake. However, his same-ticker transaction history at KNSA shows mixed timing outcomes: of 5 prior trades, only 1 has a measurable 90-day outcome (2024-12-09 sale with +0.6% 90d return), meaning 0 of 1 prior same-ticker sales were well-timed. More notably, the current stock price of $29.52 is +0.0% from the 52-week high and the 90-day return from this June 2025 sale is positive (+37.2%), indicating the stock has risen substantially since the sale was executed. This outcome—where the insider sold and the stock subsequently rallied—is poorly timed and contrasts with a cross-ticker track record showing a 33.33% well-timed rate on sells. The company posted $137.8M quarterly revenue with $8.5M net income and +56.6% annual revenue growth, though it remains unprofitable on a full-year basis.

KNSA CFO Ragosa sells 88,395 shares for $2.3M across 3 days; 76.6% of holdings now gone

Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals, executed 3 separate sales totaling 88,395 shares for $2,347,335.10 over April 29–May 1, 2025, reducing his holdings by 76.6% from 115,404 shares to 27,009 shares. The sales occurred at $25.61, $26.95, and $27.80 per share (blended average $26.56) against a current price of $27.74, placing the average sale price 4.3% below market. His prior KNSA sales (4 trades in the past year) show a 0% well-timed rate at the 90-day mark, with mixed 30-day outcomes ranging from -13.2% to +5.7%, indicating no consistent pattern of anticipating price movement at this ticker. The company reported $137.8M in latest quarterly revenue (+56.6% annual growth) alongside positive quarterly net income of $8.5M, though it ran at a loss for the full prior fiscal year; this near-breakeven transition does not obviously flag operational distress, leaving the scale and timing of the near-total divestment as the key interpretive question for investors monitoring executive positioning.

CFO Ragosa Mark sells 36.4K shares of KNSA at $22.25, reducing holdings 61.3% to 23.0K shares

CFO Mark Ragosa sold 36,372 shares (61.3% of his pre-transaction holdings) at $22.25 on 2025-03-12, bringing his position from 59,330 to 22,958 shares. The company is currently unprofitable with net income of $-12.7M in the latest quarter, though revenue of $112.2M represents 56.6% annual growth. At the same-ticker level, Ragosa's three prior KNSA sales over the past eight months have demonstrated a 0 of 3 well-timed rate at the 90-day mark; his most recent two December sales preceded modest declines (90d returns of +0.6% and +0.0%), while his July 2024 sale saw the stock rise 4.4% over 90 days. The substantial reduction in insider ownership post-sale warrants investor attention given the company's unprofitable state and the insider's recent pattern of sales.

CFO Ragosa Mark sold 27,829 shares at blended $21.34 on Dec 6 & 9; holding reduced 54.8% to 23.0K shares

Mark Ragosa, CFO of Kiniksa Pharmaceuticals, executed two separate sales totaling 27,829 shares for $593,997.43 at a blended average price of $21.34, reducing his holdings by 54.8% from 50,787 to 22,958 shares. The stock has since declined 6.3% over 30 days and 12.0% over 90 days from the transaction dates, moving 22.4% below its 52-week high of $27.59. His prior sale at this ticker on 2024-07-23 posted positive 30-day and 90-day returns, indicating the stock rose after that earlier sale—a pattern that did not repeat following this latest transaction. The company shows strong revenue growth of 22.7% year-over-year but carries a net loss of $12.7M against quarterly revenue of $112.2M and an elevated P/E of 107.05, creating an asymmetric risk profile.